The emerging role of CaMKII in cancer

Yan-yang Wang; Ren Zhao; Hong Zhe

doi:10.18632/oncotarget.3955

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The emerging role of CaMKII in cancer

Yan-yang Wang, Ren Zhao and Hong Zhe _

PDF | HTML | How to cite

Oncotarget. 2015; 6:11725-11734. https://doi.org/10.18632/oncotarget.3955

Metrics: PDF 3219 views | HTML 5509 views | ?

Abstract

Yan-yang Wang1,2, Ren Zhao1,2 and Hong Zhe1,2

1 Department of Radiation Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China

2 Cancer Institute, Ningxia Medical University, Yinchuan, Ningxia, China

Correspondence to:

Hong Zhe, email:

Keywords: Ca2+/calmodulin-dependent protein kinase II (CaMKII), cancer, cell cycle, therapeutic target, CaMKII inhibitor

Received: January 10, 2015 Accepted: April 08, 2015 Published: April 29, 2015

Abstract

Ca2+/calmodulin-dependent protein kinase II (CaMKII) is a multifunctional serine/threonine kinases best known for its critical role in learning and memory. Recent studies suggested that high levels of CaMKII also expressed in variety of malignant diseases. In this review, we focus on the structure and biology properties of CaMKII, including the role of CaMKII in the regulation of cancer progression and therapy response. We also describe the role of CaMKII in the diagnosis of different kinds of cancer and recent progress in the development of CaMKII inhibitors. These data establishes CaMKII as a novel target whose modulation presents new opportunities for cancer diagnosis and treatment.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 3955

Publication Alerts

Reviews:

The emerging role of CaMKII in cancer

Abstract